6.
Kantarjian H, DeAngelo D, Stelljes M, Martinelli G, Liedtke M, Stock W
. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016; 375(8):740-53.
PMC: 5594743.
DOI: 10.1056/NEJMoa1509277.
View
7.
Topp M, Gokbuget N, Stein A, Zugmaier G, OBrien S, Bargou R
. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2014; 16(1):57-66.
DOI: 10.1016/S1470-2045(14)71170-2.
View
8.
Kiyoi H, Morris J, Oh I, Maeda Y, Minami H, Miyamoto T
. Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia. Cancer Sci. 2020; 111(4):1314-1323.
PMC: 7156857.
DOI: 10.1111/cas.14322.
View
9.
Sakura T, Hayakawa F, Sugiura I, Murayama T, Imai K, Usui N
. High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG. Leukemia. 2017; 32(3):626-632.
DOI: 10.1038/leu.2017.283.
View
10.
Kantarjian H, Stein A, Gokbuget N, Fielding A, Schuh A, Ribera J
. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017; 376(9):836-847.
PMC: 5881572.
DOI: 10.1056/NEJMoa1609783.
View
11.
Kebriaei P, Cutler C, de Lima M, Giralt S, Lee S, Marks D
. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018; 53(4):449-456.
PMC: 5897380.
DOI: 10.1038/s41409-017-0019-y.
View
12.
Rowe J, Buck G, Burnett A, Chopra R, Wiernik P, Richards S
. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005; 106(12):3760-7.
DOI: 10.1182/blood-2005-04-1623.
View
13.
von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett T, Rizzari C
. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. J Clin Oncol. 2016; 34(36):4381-4389.
DOI: 10.1200/JCO.2016.67.3301.
View
14.
Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R
. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer. 2005; 115(1):98-104.
DOI: 10.1002/ijc.20908.
View
15.
Martinelli G, Boissel N, Chevallier P, Ottmann O, Gokbuget N, Topp M
. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter.... J Clin Oncol. 2017; 35(16):1795-1802.
DOI: 10.1200/JCO.2016.69.3531.
View
16.
Yuen C, Rezania K, Kelly T, Bishop M
. Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study. Immunotherapy. 2021; 13(15):1261-1269.
DOI: 10.2217/imt-2021-0084.
View
17.
Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle P
. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol. 2005; 43(6):763-71.
DOI: 10.1016/j.molimm.2005.03.007.
View
18.
Lee D, Santomasso B, Locke F, Ghobadi A, Turtle C, Brudno J
. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2018; 25(4):625-638.
DOI: 10.1016/j.bbmt.2018.12.758.
View
19.
Thomas X, Boiron J, Huguet F, Dombret H, Bradstock K, Vey N
. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004; 22(20):4075-86.
DOI: 10.1200/JCO.2004.10.050.
View